Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242514 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,917
- Enrollment target
NCT01242514 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,917 participants.
The verdict
NCT01242514, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,917 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).
Interventions
- DRUG Fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,917 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01242514
The ClinicalTrials.gov registry entry for NCT01242514 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,917 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fostamatinib is the first listed.
NCT01242514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01242514 about?
NCT01242514 is a clinical study titled "Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)". The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).
What is the current status of trial NCT01242514?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,917 participants. The study started on 2011-01. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01242514?
The interventions under investigation include: Fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01242514?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.